Completed PHASE4 INTERVENTIONAL 2-arm NCT06168084

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Sponsor: Yongquan Shi

Conditions Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer

Interventions Bismuth Esomeprazole Furazolidone Tetracycline Vonoprazan amoxicillin

Updated 6 times since 2024 Last updated: Jul 1, 2025 Started: Jun 6, 2023 Primary completion: May 30, 2024 Completion: Aug 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer and is currently completed. Yongquan Shi leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Aug 2025 — Sep 2025 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE4
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yongquan Shi

Data source: Xijing Hospital of Digestive Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China
• Xi’an, China